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Abstract
Background: Respiratory diseases are mainly derived from acute and chronic inflammation of the alveoli and
bronchi. The pathophysiological mechanisms of pulmonary inflammation mainly arise from oxidative damage
that could ultimately lead to acute lung injury. Apigenin (Api) is a natural polyphenol with prominent anti-
oxidant and anti-inflammatory properties in the lung. Inhalable formulations that consist of nanoparticles (NPs)
have several advantages over other administration routes, and therefore, this study investigated the application
of apigenin-loaded bovine serum albumin nanoparticles (BSA-Api-NPs) for pulmonary delivery.
Methods: Dry powder formulations of BSA-Api-NPs were prepared by spray drying and characterized by laser
diffraction particle sizing, scanning electron microscopy, differential scanning calorimetry, and powder X-ray
diffraction. The influence of dispersibility enhancers (lactose monohydrate and l-leucine) on the in vitro aerosol
deposition using a next-generation impactor was investigated in comparison to excipient-free formulation. The
dissolution of Api was determined in simulated lung fluid by using the Franz cell apparatus. The antioxidant
activity was determined by 2,2-diphenyl-1-picrylhydrazyl (DPPHc) free radical scavenging assay.
Results: The encapsulation efficiency and the drug loading were measured to be 82.61%– 4.56% and
7.51%– 0.415%. The optimized spray drying conditions were suitable to produce particles with low residual
moisture content. The spray-dried BSA-Api-NPs possessed good aerodynamic properties due to small and
wrinkled particles with low mass median aerodynamic diameter, high emitted dose, and fine particle fraction.
The aerodynamic properties were enhanced by leucine and decreased by lactose, however, the dissolution was
reversely affected. The DPPHc assay confirmed that the antioxidant activity of encapsulated Api was preserved.
Conclusion: This study provides evidence to support that albumin nanoparticles are suitable carriers of Api and
the use of traditional or novel excipients should be taken into consideration. The developed BSA-Api-NPs are a
novel delivery system against lung injury with potential antioxidant activity.
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Introduction
Respiratory diseases are thought to be mainly de-rived from acute and chronic inflammation of the alveoli
and bronchi. The pathophysiological mechanisms of pul-
monary inflammation arise from several factors, including
oxidative damage due to cytotoxic mediators that may ulti-
mately lead to acute lung injury (ALI), acute respiratory
distress syndrome, and cancer.(1) A growing body of scien-
tific data suggests that natural occurring compounds possess
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preventive and therapeutic properties with inherent low
toxicity.(2) Among phytochemicals, apigenin (Api; Fig. 1) is
a promising candidate as a therapeutic agent, mainly due to
its antioxidant and anti-inflammatory properties.(3–6) It has
been demonstrated that Api has protective effects against
bleomycin-induced lung fibrosis in rats, which is associated
with its antioxidant and anti-inflammatory capacities.(7)
Another study provided evidence that Api was able to
decrease oxidative stress and inflammation on paraquat-
induced ALI in mice(8) and reduced the pathological alter-
ations of pulmonary tissue in acute pancreatitis-associated
ALI, therefore suggesting protection in the lung.(9) Fur-
thermore, Api has an anti-inflammatory effect owing to
significant inhibition of proinflammatory cytokines, activa-
tor protein (AP-1), and cyclooxygenase-2 (COX-2) in hu-
man pulmonary epithelial cells(10) and in mice as well.(11)
However, Api has low water solubility (2.16lg/mL at pH
7.5), and therefore, it was recently classified as Bio-
pharmaceutical Classification System (BCS) II drug.(12)
Encapsulation and delivery of phytoconstituents with
health effects have attracted much attention in recent years.
Developing a suitable carrier system is essential to improve
the overall activity and reduce the possible toxicity of these
agents.(13) Among the potential carrier systems, serum al-
bumin nanoparticles have notable advantages, including bio-
degradability, nonantigenicity, and cell-targeting ability.(14,15)
Moreover, albumin provides exceptional ligand binding
capacity for various drugs owing to three homologous do-
mains with two separate helical subdomains.(16) Studies
reported the successful incorporation of flavonoids into al-
bumin nanoparticles that can improve their stability(17) and
antitumor activity.(18)
Pulmonary delivery of pharmacologically active ingredi-
ents is extensively studied due to prominent advantages over
other delivery routes of administration.(19) The lungs have
a large surface area, limited enzymatic activity, and high
permeability; therefore, drugs can be delivered either locally
for the treatment of respiratory diseases or systematically to,
for example, avoid first-pass metabolism.(20) Dry powder
inhaler products offer precise and reproducible delivery of
fine drug particle fraction to the deep lung and recent studies
have proved that these are more cost-effective than other
products.(21) This noninvasive delivery route could be suit-
able for poorly water soluble drugs in nanoparticles with
increased solubility.(22)
It is also well recognized that nanoparticles have benefits
over other carriers in the micron scale such as controlled
drug release, avoiding mucociliary clearance, and improved
deposition.(23,24) Albumin is naturally present in the body, as
well as in the lung epithelium,(24) moreover, the body can
absorb proteins into the bloodstream by transcytosis, which
occurs deep in the lung and allows drug molecules to pass
through cell membrane.(25) Therefore, the presence of bo-
vine serum albumin (BSA) in the nanoparticle system in-
creases membrane permeability and may facilitate epithelial
cell uptake and translocation through the alveolar-capillary
barrier of the lung.(26) It was proved that albumin nano-
particles have high biocompatibility in a wide dose range and
remained longer in the lungs with low systemic exposure.(24)
Thus, encapsulation of apigenin into albumin nanoparticles
would enhance its solubility and distribution in the lung.
However, the formulation of dry powders with optimal
aerodynamic properties for pulmonary drug delivery is
challenging. Spray drying is a technique for manufacturing
respirable dry powders in one step. During the process, the
liquid phase is atomized into droplets that dry rapidly in the
drying chamber due to compressed air. The process condi-
tions such as heat, flow rate, aspiration rate, and pump rate
also determine the quality of the product. The thermal
degradation caused by overheating can be avoided by the
rapid evaporation of the solvent.(27) Hence, it is suitable for
drying colloidal systems resulting in uniform particle mor-
phology.
Nanoparticle delivery systems targeted to the lungs offer
several advantages such as sustained release, increased local
drug concentration, and targeted site of action.(28) Moreover,
improved drug solubility, uniform dose distribution, and
fewer side effects can be achieved, compared to conven-
tional dry powders. In general, respirable nanoparticles are
embedded in microparticles in aerodynamic size range.(26)
The aim of this work was to develop a novel dry powder
formulation against ALI caused by oxidative stress. The
prepared albumin nanoparticles were characterized in terms
of size, zeta potential, and drug loading; in addition, the
fluorescence properties were investigated. Following this,
the nanoparticles were spray dried with two types of ex-
cipients, namely a traditional lactose monohydrate and a
novel amino acid, l-leucine. In vitro aerosol deposition
patterns were determined in comparison to an excipient-free
formulation using a next-generation impactor (NGI), and a
dissolution test was performed in simulated lung fluid by
using Franz cell apparatus. Laser diffraction particle sizing,
morphology, and residual moisture content were measured
along with the antioxidant activity.
Materials and Methods
Apigenin (Api) was purchased from (purity >99%)
Hangzhou DayangChem Co., Ltd. (China). BSA powder
(purity ‡98%), L-leucine, analytical-grade chloroform, ace-
tonitrile, and trifluoroacetic acid (TFA) were obtained from
Sigma Aldrich Ltd. (Dorset, United Kingdom). Lactohale
LH 230 was supplied by Friesland Foods Domo (Amersfoort,
The Netherlands). 2,2-Diphenyl-1-picrylhydrazyl (DPPHc)
free radical was purchased from Sigma Aldrich (Darmstadt,
Germany). For the solubility and drug release study, PBS
buffer was purchased (Sigma Aldrich Ltd.) and modified
simulated lung fluid with 0.02% (w/v) (mSLF) was prepared.
All of the materials for the mSLF were purchased from
Sigma Aldrich Ltd.FIG. 1. Molecular structure of apigenin.
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Preparation of BSA-NPs
BSA nanoparticles were prepared using a nanoparticle
albumin-bound technology with minor modifications.(29)
Briefly, 1000mg of BSA was dissolved in 50mL of distilled
water saturated with chloroform. Separately, 100mg of Api
was dissolved in 3mL of chloroform saturated with water and
ultrasonicated for 10 minutes. These two solutions were mixed
and ultrasonicated for 20 minutes with a probe-type sonicator
(MSE Soniprep 150 Ultrasonic Processor; MSE Ltd., London,
United Kingdom) on ice. After homogenization, the chloro-
form was evaporated by rotary evaporator (Rotavapor R-10;
BU¨CHI Labortechnik AG, Flawil, Switzerland) at 25C for 15
minutes. The obtained nanoparticles were filtered through
filter paper (0.45lm; Fisher Scientific Ltd., Loughborough,
United Kingdom) and further spray dried.
Characterization of BSA-Api-NPs
Particle size and zeta potential analysis. The average
particle size and polydispersity index (PDI) were determined
by dynamic light scattering using Zetasizer Nano ZS instru-
ment (Malvern Instruments Ltd., Worcestershire, United
Kingdom). Zeta potential of the particles was quantified with
laser doppler velocimetry using the same instrument. All
measurements were performed in triplicate (n= 3) at 25C
and presented as mean– standard deviation.
Determination of drug loading and encapsulation efficien-
cy. To determine the amount of Api, 1mL sample from the
BSA-Api formulation was withdrawn and the apigenin
content was determined in mg/mL by adding 5mL of di-
methyl sulfoxide and methanol (DMSO:MeOH, 50:50% v/
v) and sonicated for 10 minutes. The exact concentrations
were determined after filtration (0.22 lm) by HPLC 1260
(Agilent Technologies, Inc., Santa Clara, CA) using the
reverse-phase C18 column (Phenomenex
, 250· 4.6mm,
4 lm) as the stationary phase. The temperature was set to
25C. The mobile phase consisted of 40% acetonitrile and
60% water containing 0.1% (v/v) TFA. The system was run
isocratically at the flow rate of 1.2mL/min and the Api was
detected at 340 nm (tR = 8.3). The injection volume was set
to 10 lL. A calibration curve was conducted by diluting
stock solution (0.1mg/mL) with R2 value of 0.999.
The drug loading efficiency (DL, %) and encapsulation
efficiency (EE, %) were calculated according to the equa-
tions (Eqs. 1 and 2), comparing the encapsulated Api con-
tent (mg/mL, Wencapsulated) to total nanoparticle system,
which means the weighted amount of BSA and Api together
(mg/mL, Wtotal) and the amount of Api (mg/mL, Wtheoretical)
used in the formulations.
DL (%)¼ Wencapsulated
Wtotal
· 100 (Eq: 1)
EE (%)¼ Wencapsulated
Wtheoretical
· 100 (Eq: 2)
Fluorescence spectroscopy. The fluorescence emission
spectra of BSA and BSA-Api-NPs were measured with the
Jobin Yvon-Horiba Fluoromax-3 (Paris, France) spectroflu-
orometer. The samples that contained the nanoparticles were
diluted 10 times, and the fluorescence emission spectra were
recorded between 300 and 450 nm at 25C where the exci-
tation wavelength was set to 285 nm. The data collection
frequency was 0.5 nm and the integration time was 0.2 sec-
ond. The excitation slit was set at a bandpass width of 2 nm
and the emission slit at 5 nm. Each spectrum was recorded
three times and the mean values were calculated automati-
cally. The SPSERV V3.14 software (ª Csaba Bagyinka,
Institute of Biophysics, Biological Research Center of the
Hungarian Academy of Sciences, Szeged, Hungary) was used
for baseline correction, for five-point linear smoothing, and
for the correction to the wavelength-dependent sensitivity
changes of the spectrofluorometer. The subtraction of the
Raman band at 390 nm was performed.
To obtain the three-dimensional (3D) projections and
contour maps of fluorescence spectra of the samples, the
fluorescence emission was recorded from 265 to 450 nm
using different excitation wavelengths from 250 to 310 nm
with 10 nm steps with the same instrument mentioned
above. All emission scan ranges were set to start at least
15 nm away from the corresponding excitation wavelengths.
Other settings were similar as described above. Each spec-
trum was recorded three times and the mean values were
calculated automatically. The 3D fluorescence spectra were
visualized with the software SURFER Version 10 (Golden
Software, Inc., Golden, CO). Spectra were combined to-
gether into a 3D surface data set with axes of excitation and
emission wavelengths and fluorescence intensity. Data were
also converted into two-dimensional contour maps.
Spray drying of BSA-Api-NPs
Spray drying of the BSA-Api formulations without ex-
cipient and in the presence of lactose monohydrate (50%,
w/w) and l-leucine (9%, w/w) was carried out in a BU¨CHI
290 Mini Spray Dryer (BU¨CHI Labortechnik AG, Flawil,
Switzerland). The concentration of the excipients was with
respect to the mass of the nanoparticles before spray drying.
The following operating conditions were used based on pilot
experiments: inlet temperature 120C, approximate outlet
temperature 65C–70C, the drying airflow 600 L/h, aspi-
ration rate 100% (35m3/h), the nozzle diameter was 0.1mm,
and the liquid feed rate was set to 5mL/min. Each prepa-
ration was carried out in triplicate. Following spray drying,
the powders were collected from the lower part of the cy-
clone and the collecting vessel, stored in tightly sealed glass
vials under vacuum at room temperature.
Characterization of spray-dried BSA-Api-NPs
Determination of residual moisture. The moisture con-
tent of the spray-dried powders was measured by using Karl
Fischer titration (Metrohm 758 KFD Titirino; Metrohm AG,
Lichtenstein, Switzerland). For that purpose, *100mg of
the product was analyzed and the instrument was previously
calibrated with 10 lL distilled water. The evaluation was
conducted in triplicate and the standard deviation calculated.
Fourier transform infrared spectroscopy. Fourier trans-
form infrared spectroscopy (FT-IR) spectra of BSA-Api
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spray-dried samples were evaluated using a PerkinElmer
Spectrum 100 FT-IR spectrometer equipped with Universal
ATR (attenuated total reflectance) accessory (PerkinElmer,
Inc., Waltham, MA). Approximately 2mg of the solid
samples was placed between the plate and the probe. The
spectra were recorded with three scans, in the frequency
range between 4000 and 600 cm-1 and with a resolution of
4 cm-1 at room temperature. The data were analyzed using
the PerkinElmer Spectrum Express software.
X-ray powder diffraction. X-ray powder diffraction
(XRPD) diffractograms were obtained using an X-ray dif-
fractometer (MiniFlex600; Rigaku Corporation, Tokyo,
Japan). The analyses were performed at room temperature
and the samples were scanned from 2 to 40 2h using a
scanning speed of 2/min with a step size of 0.05.
Differential scanning calorimetry analysis. The spray-
dried formulations were characterized by differential scanning
calorimetry (DSC) (DSC Q2000 module; TA Instruments,
New Castle, United Kingdom), which was calibrated using
indium. Samples (3–5mg) were weighed accurately and
analyzed in sealed and pierced aluminum hermetic pans (TA
Instruments). The pans were equilibrated at 25C and then
heated at a rate of 10C/min in a range of 50C–400C.
Aerosol particle size analysis and redispersibility in wa-
ter. The particle size analysis was conducted by using a
Sympatec HELOS laser diffractometer (Sympatec GmbH
System-Partikel-Technik, Clausthal-Zellerfeld, Germany).
The powders were dispersed by compressed air (4–5 bar)
into the measuring zone of the laser beam. The optical lens
(0.45–87.5 lm size range) focused onto the detector to
collect the diffracted light for calculation of size distribu-
tion. The values of 10th (D10), 50th (D50), and 90th (D90) of
the cumulative particle size distribution are generated.
Samples were measured in triplicate.
The particle size was also determined after spray drying.
Five milligrams of dry powder of each formulation could be
easily redispersed in 5mL distilled water and the particle
size was determined without any further dilution by the
abovementioned Zetasizer Nano ZS instrument (Malvern
Instruments Ltd., Worcestershire, United Kingdom).
Solubility and drug release studies of BSA-Api formula-
tions. The solubility of BSA-Api formulations was deter-
mined in PBS buffer (pH 7.4) and in mSLF (pH 7.4), which
contained 0.02% (w/v) DPPC, prepared according to Son
and McConville.(30) Fifty milligrams of samples of spray-
dried powders was added to 100mL solvent and shaken
(150 rpm) for 2 hours at 37C. At predetermined time points,
1mL of samples was taken from each dissolution medium
and replaced with the same volume of fresh medium. All of
the samples were diluted with 1mL methanol and filtered
with Amicon Ultra Centrifugal filters (30K; Merck Millipore,
Merck KGaA, Germany) before the injection and the amount
of apigenin was determined by the HPLC-UV method.
The in vitro drug release study of the three formulations
was conducted with the Franz cell apparatus. The mSLF was
used as dissolution media and a 0.45 lm cellulose acetate
membrane filter (Sartorius AG, Gottingen, Germany) was
applied.
Briefly, an accurately weighed amount (10mg) of spray-
dried nanoparticles of each formulations were scattered onto
the membrane, which was previously wetted with the dis-
solution media for 1 hour. One milliliter of samples was
withdrawn at various time intervals for 5 hours and replaced
with fresh dissolution medium. After the measurement,
membrane was rinsed with 2mL of MeOH and the drug
content of the possibly remained powders was determined.
The sample preparation and the measurement were the same
as mentioned above. The cumulative amount of apigenin
release over the time was plotted for each formulation. All
measurements were performed in triplicate.
Aerosol delivery of BSA-Api formulations. In vitro aero-
dynamic performance of BSA-Api formulations was as-
sessed using the NGI (Copley Scientific Ltd., Nottingham,
United Kingdom), connected sequentially to a low-capacity
pump via the critical flow controller (Model LCP5; Copley
Scientific Ltd.). During the measurement, the pump was
operated at an air flow rate of 60 L/min for 4 seconds. The
3 · 10mg powder aliquots from each formulation were
loaded manually into gelatin capsules (size 3) and placed
into the inhaler device (Cyclohaler; Pharmachemie, Lon-
don, United Kingdom), which was connected to the NGI via
an airtight rubber adaptor and a stainless steel United States
Pharmacopeia (USP) throat. The NGI stages were assem-
bled with an induction port and a preseparator, and a filter
was placed in the final stage.
Before the impaction, the collection plates were uni-
formly coated with 1mL of 1% silicone oil in N-hexane
solution and allowed to dry, leaving a thin film of silicone
oil on the plate surface to prevent the re-entrainment of
the particles and the preseparator was filled with 15mL
DMSO:MeOH (50:50%, v/v) mixture. After the deposition
of the powders in the NGI, the amount of each formulation
was cumulatively collected onto silicone-coated plates for
each of the stages. The inhaler, mouthpiece, induction port,
preseparator, and the collection plates were rinsed with
DMSO:MeOH (50:50%, v/v) mixture, collected in volu-
metric flasks (10 or 25mL), and made up to volume. The
samples were determined by using the HPLC method as
described previously.
To characterize the aerosol performance, the following
parameters were calculated based on the drug mass of each
fraction: emitted dose (ED, %): the percentage of the entire
dose depositing from the mouthpiece of the inhaler device
and recovered dose (RD, %): the total recovered drug mass.
The fine particle fraction (FPF, <4.46 lm) is defined as the
percentage of the ED, deposited from Stage 2–7 and the
micro-orifice collector. The mass median aerodynamic di-
ameter (MMAD) and geometric standard deviation (GSD)
were calculated from the inverse of the standard normal
cumulative mass distribution against the natural logarithm
of the effective cutoff diameter of the respective stages. All
measurements were carried out in triplicate.
Particle morphology. Morphology of Api powder and
spray-died nanoparticles was examined using scanning
electron microscopy (SEM) analysis. The dry powder of the
formulations was placed on the sample holder using a
double adhesive tape, and gold coating (*20 nm thickness)
was applied. Examinations were performed by the FEI
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Inspect S50 (Hillsboro, OR) scanning electron microscope
at 20.00 kV accelerating voltage. Original magnifications
were 8000 · , 10,000· , and 20,000·with accuracy of –2%.
Antioxidant activity
The antioxidant activities of the prepared spray-dried
formulations were compared to the pure Api to investigate
the effectiveness of the formulation. The free radical scav-
enging activity was measured by using DPPHc method as
described previously,(31) with slight modifications. Metha-
nolic stock solution of 0.1mM DPPHc reagent was freshly
prepared and protected from light. Standard curve was
plotted between the DPPHc concentration (0.01–0.1mM)
and absorbance, the linear relationship was calculated
graphically. One milliliter of MeOH was added to the BSA-
Api-NPs and the concentration of Api was the same in each
sample for comparability. Thereafter, 2mL of 0.06mM
DPPHc reagent was added to the samples, vortex mixed for
10 seconds, and protected from light.
The absorbance at 517 nm was determined with a spec-
trophotometer (UV-Vis spectrophotometer, Metertech SP-
8001; Metertech, Inc., Taipei, Taiwan) every 15 minutes
until the steady state (when no further discoloration could be
observed). The addition of samples resulted in a decrease in
the absorbance of DPPHc due to the scavenging activity of
Api. The exact concentration of the free radical was calculated
using the standard curve. To calculate the inhibition of the free
radical DPPHc, the following equation (Eq. 3) was used:
I(%)¼ A0As
A0
· 100 (Eq: 3)
Where I (%) is the inhibition in percent, A0 is the absor-
bance of the DPPHc solution, and As is the absorbance of the
sample. All measurements were carried out triplicate and the
data are expressed as the mean value – standard deviation.
Results and Discussion
Characterization of BSA-Api-NPs
Size, zeta potential, and drug content. Albumin is a
natural protein that has been widely used as a macromolec-
ular carrier for many drugs with low water solubility. Several
techniques are available to prepare albumin nanoparticles,
including desolvation (coacervation), nab (nanoparticle al-
bumin bound) technology, and self-assembly.(14) In this
study, the BSA-Api-NPs were prepared by using modified
nab technology with ultrasonication. The achieved mean
particle size of three samples was 376– 7.824 nm with a PDI
of 0.285– 0.01. The size of albumin NPs less than 500 nm
could localize effectively in the lung. The PDI value indi-
cated narrow particle size distribution and the uniformity of
the nanoparticles. The zeta potential was -19.20– 0.818mV.
The higher the zeta potential, the more stable the formulation
is, less aggregation occurs.(32)
The EE was determined to be 82.61%– 4.56% and the DL
was 7.51%– 0.415%. Therefore, these results confirmed the
high encapsulation efficiency of apigenin by BSA-NPs and
that it can be an attractive tool in encapsulation of flavo-
noids for delivery. Similar data were found in the literature
when encapsulating flavonoids into albumin nanoparticles.
Human serum albumin (HSA)-bound curcumin nano-
particles resulted in 7.2% – 2.5% loading efficiency(33) and
scutellarin-loaded BSA nanoparticles possess 64.46% EE
and 6.73% DL.(34)
Fluorescence spectroscopy. The phenomenon of fluo-
rescence quenching can result from various inter- and in-
tramolecular interactions suchas energy transfer, conformational
changes, complex formation (static quenching), or collisional
interaction (dynamic quenching). During static quenching, the
quencher forms a stable nonfluorescent complex with the fluor-
ophore, however, during dynamic quenching it collides with the
fluorophore and facilitates nonradiative transitions to the ground
state.(35) Therefore, quenching of the intrinsic fluorescence of the
two tryptophan residues (Trp-134 andTrp-212) ofBSAcanoffer
information about the changes in molecular microenvironment
of these fluorophores, located in domain I and II, respectively.
Trp-134 residue is located close to the protein surface in a hy-
drophilic environment, whereas Trp-212 is within a protein
pocket that is hydrophobic (subdomain II A). The Trp-214
in HSA is located similarly to Trp-212 in BSA.(36–38)
The quenching effect of Api on fluorescence intensity of
serum albumins (BSA and HSA) has been studied previ-
ously,(36,39–42) but there are no data related to its behavior in
a nanoparticulate system. Studies have shown that the in-
creasing concentration of Api resulted in a decrease in the
fluorescence emission intensity of serum albumin solutions.
This was mainly attributed to complex formation (static
quenching), however, it could be dynamic quenching at
higher Api concentrations.(42) Nevertheless, all studies
concluded that Api most likely binds to the subdomain IIA
of Site I side with electrostatic and hydrophobic interac-
tions, through which H-bonds and nonradiative energy
transfer can occur. The binding could affect the conforma-
tion of Trp microregion, but the secondary structure of se-
rum albumin is not altered.(36,39,41) However, the pH and
ionic concentrations (e.g., NaCl) can affect the fluorescence
quenching on the binding parameters of apigenin to BSA.(43)
Figure 2 demonstrates the fluorescence emission spec-
tra of BSA solution, BSA-NPs, and BSA-Api-NPs. The
FIG. 2. Fluorescence emission spectra of BSA solution,
BSA nanoparticles, and BSA-Api nanoparticles. The exci-
tation wavelength was set to 285 nm. BSA, bovine serum
albumin.
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fluorescence intensity of BSA-NPs decreased slightly com-
pared to BSA solution with no obvious shift of the maxi-
mum position at 350 nm. It was probably due to the
conformational changes of the protein. The significantly
lower emission intensity of BSA-Api-NPs indicates that Api
could quench the fluorescence of BSA, which is also re-
flected on the 3D projections (Fig. 3). All of these findings
indicate that Api binds to the Trp region (Trp-212, sub-
domain II A), but the spectral maximum was not affected,
and therefore, hydrophobicity and polarity of the fluor-
ophore residues are not altered. It was concluded that Api
can be bound to the Trp region of serum albumin nano-
particles similarly to the solutions.
Characterization of spray-dried BSA-Api-NPs
Determination of residual moisture. Moisture content is
mainly influenced by the spray drying conditions. Increased
heat energy availability provided by regulating inlet air
temperature and aspirator capacity allows more efficient
drying, thus resulting in the lower moisture content demon-
strated. However, degradation of heat-sensitive materials
such as proteins may occur; therefore, inlet air temperature
should be kept below 120C.(44) The water content is also
affected by the type of excipients and the ratio with the na-
noparticles.(45) Moisture content is an important factor that
can significantly influence the aerodynamic properties of
aerosols. It can change the surface of particles, promote ag-
gregation, and influence the crystallinity of the spray-dried
samples.(44)
In this study, the residual water content was determined
by using Karl Fisher titration. All formulations had rela-
tively low moisture content, which followed the rank
order of l-leucine (4.11%– 0.21%, w/w) < excipient-free
(4.55% – 0.49%, w/w) < lactose (5.8%– 0.36%, w/w) con-
taining products. These results demonstrate that the opti-
mized outlet air temperature (around 65C) was suitable for
serum albumin. The l-leucine containing formulation had
the lowest water content due to the low hygroscopic be-
havior of this amino acid.(46,47) The low moisture content
can potentially improve the flowability and consequently
enhance lung deposition due to reduced aggregation as ex-
pected. Storage conditions are also important, for example,
the spray-dried amorphous lactose particles could transform
into crystals easily in humidity above 30%.(48)
Fourier transform infrared spectroscopy. FT-IR analysis
allows a quick and efficient identification of the compounds
and by their functional groups and bond vibrations. In the
spectrum of raw Api, the following characteristic regions
were observed: 2710–2580 cm-1 O-H bond, 1730–1680 cm-1
C=O stretch, and 1450–1380 cm-1 C-H bend. A broad peak
observed at 3300 cm-1 can be attributed to O-H stretching and
those bands at 1600–1400 cm-1 (C-C stretch in ring) and
900–675 cm-1 (C-H ‘‘oop’’) can be assigned to the aromatic
group (Fig. 4A). In the spectrum of BSA protein, the amide I
band at 1635 cm-1 (mainly C=O stretch) and amide II band
at 1530–1500 cm-1 (C–N stretching and N–H bend) can be
seen. The medium broad peak at 3276 cm-1 corresponds to
bonded N-H stretch of amide and a smaller band at 1057 cm-1
FIG. 3. Three-dimensional fluorescence emission maps and two-dimensional contour maps of empty
BSA nanoparticles and BSA-Api nanoparticles. Color scale displays the range of observed fluorescence
intensities. EM, emission; EXC, excitation.
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is the C-N stretch of aliphatic amine. In the spectra of the
excipient-free formulation, the characteristic amide bands of
BSA can be seen and peak at 830 cm-1 indicating the pres-
ence of Api (aromatic), which is an indirect confirmation of
Api encapsulation on BSA-NPs. Conformational changes can
be suggested due to the lack of the peak of aliphatic amine.
The spectra of raw Api, BSA, lactose, and lactose con-
taining product are displayed in Figure 4B. In the spectra of
lactose, there is also a broad band around 3300 cm-1 indi-
cating the stretching vibration of hydroxyl group. A weak
band at 1654 cm-1 is the bending vibration of the crystalline
water and peaks at 1200–1070 cm-1 demonstrating the
stretching vibration of C-O-C in the glucose and galactose.
The spectrum of amorphous lactose has the less number and
defined peaks and therefore it could be distinguished from
the crystalline spectrum.(49) The characteristic broad band
at 3300 cm-1 in the spectrum of spray-dried product could
originate from the residual water content that is further
supported by the Karl Fischer titration data (lactose con-
taining product had the highest water content). Similarly to
the spectrum of excipient-free formulation, the amide bands
of BSA and a small peak of Api could be observed. The
peaks at 1200–1070 cm-1 demonstrate the lactose content
and the amorphous state could be assumed.
Functional groups of l-leucine lead to its characteristic
spectrum (Fig. 4C). The strong band in the region of 2970–
2910 cm-1 can be accounted for the aliphatic C-H stretching.
The bonded N-H stretch is present in the region of 2600–
2450 cm-1. The NH2 bending and the C-N skeletal vibration
appear in the regions of 1595–1550 cm-1 and 1250–
1020 cm-1.(50) The presence of BSA characteristic peaks on
the spray-dried formulation could be mainly observed with a
small peak of Api, but the major characteristic peaks of l-
leucine are obscured.
X-ray powder diffraction. XRPD is considered to be the
most accurate method to study crystalline structure.(51) The
combined XRPD diffractograms of Api and spray-dried
FIG. 4. (A) FT-IR spectra of apigenin (1), BSA (2), and the excipient-free spray-dried BSA-Api nanoparticles (3). (B) FT-
IR spectra of apigenin (1), BSA (2), lactose (3), and spray-dried BSA-Api nanoparticles with lactose (4). (C) FT-IR spectra
of apigenin (1), BSA (2), L-leucine (3), and spray-dried BSA-Api nanoparticles with L-leucine (4). FT-IR, Fourier
transform infrared spectroscopy.
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formulations are presented in Figure 5. The characteristic
narrow diffraction peaks of Api are due to the crystalline
state of the commercially available material. In comparison,
broad diffuse peaks could be observed in the diffractograms
of the spray-dried formulations suggesting the amorphous state
of BSA-Api-NPs. The observed XRD patterns of spray-dried
l-leucine and lactose were consistent with literature.(48,52,53)
DSC analysis. The DSC curves of raw Api, excipents,
physical mixtures, and spray-dried formulations were stud-
ied to examine crystallinity. As seen in Figure 6, there is
only one sharp endothermic peak at 360C indicating the
melting point of raw Api; no impurities were observed.
Drug-free albumin exhibited two broad peaks with onset
values of 220C and 310C. The evaporation of residual
water occurred at 50–120C. The melting point of Api on
the thermograms of raw material and physical mixtures
corresponds to the crystalline habitus.
In the thermograms of physical mixtures in Figure 6B, the
endothermic peak at 140C indicating the crystalline lac-
tose(54) and the sublimation of l-leucine crystals occurred at
200C–230C (Fig. 6C).(55) However, in each spray-dried
formulation, the absence of endotherms confirms the loss of
crystallinity. No peak could be observed around 360C in-
dicating that Api is in an amorphous state due to the spray
drying process, which is in agreement with the XRPD dif-
fractograms. The amorphous form generated may result in
higher solubility of the powders and dissolution of apigenin
in lung fluids.
Aerosol particle size analysis and redispersibility in wa-
ter. Dry powder formulations of BSA-Api-NPs were pre-
pared with the aim of studying the influence of excipients on
the particle size and aerodynamic behavior. The deposition
of aerosols is significantly affected by particle size, which
should be small enough to pass through the upper airways
and large enough to avoid exhalation.(56) Gravitational
sedimentation is the main driving force for deposition of a
nanoparticulate system in the lung due to the formation of
aggregates in the micrometer size range. Particle geometry
and surface properties also play a significant role in reaching
the bronchioles.(22,32) It is well known that particles can be
deposited efficiently deeper in the lung if their aerodynamic
diameter is in the range of 1–5 lm and only those with 1–
3 lm can reach the respiratory zone.(57) Particles, larger than
5 lm, tend to deposit in the oropharynx and the mucociliary
clearance plays a role in clearing the particles toward the
pharynx. However, very small particles, less than 1 lm are
usually exhaled because of the low inertia.(58,59)
Mucociliary clearance is part of the natural defense mech-
anism of the lung as well as the phagocytosis of macro-
phages in the alveolar region. The aerosol particle size was
determined by Sympatec HELOS laser diffractometer (Ta-
ble 1). The excipient-free and lactose containing products
have similar sizes, while spray drying with l-leucine pro-
duced the smallest particles (D50 = 2.473 lm). In all cases,
the particle size could ensure the highest probability of
delivery of apigenin into the respiratory zone.
Following the redispersion of spray powder formulations
in distilled water, the size of the particles was preserved in the
nanometer size range: without excipient (358.9– 5.3 nm, PDI:
0.315– 0.013), lactose (366.1– 4.8 nm, PDI: 0.382– 0.014),
and l-leucine (343.7– 2.9 nm, PDI: 0.316– 0.011) containing
products. Spray drying has no significant effect on the aver-
age size of the particles, suggesting the deposition of apigenin
containing nanoparticles in the lung fluid. Moreover, the
excipients did not affect adversely the particle size.
Solubility and drug release studies of BSA-Api formula-
tions. The solubility of apigenin in nanoparticles was in-
vestigated in PBS buffer and mSLF (Fig. 7A). The results
showed that the solubility was slightly increased in mSLF
media (82%–98% within 5 minutes), however, it was high in
PBS buffer as well (79%–95% within 5 minutes). These data
indicated that the solubility of apigenin could be highly
enhanced by BSA nanoparticles in aqueous medium.
Nevertheless, the dispersibility enhancers could play a role
in the solubility. In case of excipient-free formulation, 91%
of the encapsulated apigenin was dissolved in mSLF within
5 minutes. Formulation prepared with lactose increased the
FIG. 5. X-ray powder diffraction pattern of raw apigenin and the formulations.
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solubility rate up to 98%, however, it was slower (82%)
when using l-leucine and completed within 2 hours. These
results could be attributed to the solubility of the excipients
themselves; lactose has very good water solubility, but l-
leucine possesses a low solubility in water.(55)
The apigenin release from the spray-dried BSA-Api-NPs
was investigated with Franz cell apparatus. It is a well-
known device for the dissolution of semisolid dosage forms
and approved by the USP. However, there is no standardized
method for inhaled powders, Franz cell could be one of the
alternative choices due to simulating the diffusion-
controlled air–liquid interface of the lung. On the contrary,
it has some limitations such as small air bubbles under the
contact area of membrane to dissolution medium, wide
range of SD, or recovery usually around maximum 90%.(60)
Based on the solubility measurements, mSLF was applied.
The cumulative dissolution curves of the prepared for-
mulations are shown in Figure 7B. As expected, the disso-
lution was affected by the cospray-dried excipients. Lactose
containing product resulted the fastest and highest apigenin
release due to the excellent water solubility. This enhance-
ment of the dissolution is supported by previously published
data.(61) In contrast, the dissolution rate was decreased when
l-leucine was applied. The coating layer of L-leucine slowed
FIG. 6. (A) DSC thermograms of apigenin (1), BSA (2), physical mixture (3), and excipient-free spray-dried BSA-Api
nanoparticles (4). (B) DSC spectra of apigenin (1), BSA (2), physical mixture (3), and spray-dried BSA-Api nanoparticles
with lactose (4). (C) DSC spectra of apigenin (1), BSA (2), physical mixture (3), and spray-dried BSA-Api nanoparticles
with L-leucine (4). DSC, differential scanning calorimetry.
Table 1. Aerosol Particle Sizes of Spray-Dried
Nanoparticles with Sympatec HELOS
Laser Diffractometer in lm
Excipient free Lactose L-leucine
ED (%) 91.862– 2.735 93.950– 1.046 95.183– 0.667
FPF (%) 65.617– 3.422 58.463– 6.031 66.090– 2.777
MMAD (lm) 3.210– 0.069 3.130– 0.001 2.123– 0.098
GSD (lm) 2.823– 0.113 2.270– 0.212 1.887– 0.063
RD (%) 99.1 – 5.012 94.7 – 4.091 96.3– 2.161
ED, emitted dose; FPF, fine particle fraction; GSD, geometric
standard deviation; MMAD, mass median aerodynamic diameter;
RD, recovered dose.
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down the dissolution of apigenin, which could be well ob-
served in the dissolution curve. The low water solubility of
l-leucine is able to hinder the dissolution of the drug, which
was published previously.(55) These results suggest that the
excipients play an important role in the solubility and the
dissolution as well.
Aerosol delivery of BSA-Api formulations. Particles can
be taken up by alveolar macrophages, which influence the
therapeutic outcome. Those nanoparticles that are soluble
and above 200 nm are able to escape from the macrophages
and therefore exhibit sustained therapeutic effect.(62) The
lung deposition and therefore the efficacy of the inhaled
therapeutics are governed by their aerosol properties.(56)
Manufacturing respirable nanoparticles could be produced
by aggregation in the favorable size range or their incor-
poration into microparticles (1–5lm).(26)
Lactose monohydrate is a well-known, traditional carrier
for improving the performance of inhaled products; how-
ever, it is influenced by physicochemical properties and
interaction with the active ingredient.(63,64) It is the only
FDA-approved carrier and has also been shown to be a
potential excipient for protein encapsulation.(27,64) Recently,
novel materials such as specific amino acids have been
developed for pulmonary formulations(26) and l-leucine is
one of the most effective dispersibility enhancer among
them.(47) Previous studies proved that 5% (w/w) l-leucine
improved the aerosol performance of raw naringin(65) and
inclusion up to 15% (w/w) l-leucine resulted in higher ED
and FPF of powder formulation of gentamicin.(46)
In this study, in vitro aerosol properties of three different
dry powder formulations were evaluated using the NGI,
which is regarded as an optimal instrument for analysis of
aerodynamic behavior of aerosol formulations for pulmonary
drug delivery(66) according to the European and US Phar-
macopeias. The obtained data and deposition pattern are
presented in Table 2 and in Figure 8. It can be seen that more
than 90% of apigenin could be recovered from the NGI,
which is in the acceptable pharmacopeia range (75–125%).
The ED ranged between 91% and 96% indicating good
flowability and high dispersibility of the powders. l-leucine
containing formulation had the highest ED as it could im-
prove significantly the flowability of the powders.(47,53)
FIG. 7. (A) Solubility of spray-dried BSA-Api formulations in PBS buffer and mSLF). (B) Dissolution
of apigenin from the formulations as a function of time in mSLF. mSLF, modified simulated lung fluid.
Table 2. Aerodynamic Characteristic
of Spray-Dried Nanoparticles
Excipient free Lactose L-leucine
D10 1.033 – 0.032 1.020 – 0.070 0.843– 0.680
D50 3.030 – 0.092 3.107 – 0.102 2.473– 0.300
D90 7.110 – 0.306 7.117 – 0.337 5.287– 0.670
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Figure 8 shows the amount of Api deposited on the throat
device and Stages 1–7 expressed as a percentage of the total
amount of recovered powder. All formulations exhibited
increased deposition in Stage 2–4, indicating enhanced
drug delivery to the alveolar regions. As expected, improved
aerosol performance and deposition (Stage 3 and 4) could be
observed when l-leucine was used an as excipient. The FPF
is one of the key parameters in aerosol delivery and should
be as high as possible.(67) In this study, the FPF values
ranged between 58% and 66%, suggesting that the particles
could be delivered into the peripheral regions. Spray drying
of nanoparticles in the presence of l-leucine resulted a
higher FPF value (66%) due to improved surface properties
and morphology of the particles.(64)
In general, MMAD values <5 lm are for pulmonary lung
delivery and between 2 and 3 lm are optimal for deep lung
deposition.(56) In each cases, the calculated MMAD data
were in agreement with the physical diameter size of the
particles measured by laser diffractometer. The data obtained
(<5lm) support good dispersibility of the particles into the
lower airways and the deep lung. Therefore, local delivery
to the alveoli could be assured by both excipient-free and
lactose formulations generated (MMAD 3.2 and 3.1lm).
Moreover, formulation with l-leucine (MMAD 2.1lm)
would be more optimal for deep lung deposition. The size
distribution of an aerosol is described best by GSD.(68) Based
on the GSD data obtained, the l-leucine containing formu-
lation had the narrowest size distribution (1.8lm) but that of
the others was also in the acceptable range (<3lm).
The overall values demonstrate that the particles of
each dry powder nanoparticle formulation are in the fa-
vorable aerodynamic size range, possess good dis-
persibility properties and particle deposition. Therefore,
BSA-NPs are an attractive delivery system for pulmonary
drug delivery. We demonstrated that l-leucine improved
better the aerosolization properties of BSA-Api-NPs than
lactose monohydrate. Therefore, it can be concluded that
the use of excipients influences the aerosol performance
of nanoparticles.
Particle morphology. SEM analysis was conducted to
investigate the morphology of the powders (Fig. 9A, B). It is
well known that the morphology of the particles is strongly
affected by the solubility of the components and the nature of
the excipients.(46,47) The commercially available Api was a
crystalline powder featuring needle-shaped crystals. The
excipient-free spray-dried nanoparticles exhibited a spherical
shape and smooth or wrinkled surface. Particles of lactose
containing product had raisin-like surface and some of the
particles were larger in accordance with the laser diffraction
particle size analysis.
Powders prepared with l-leucine comprised small and
collapsed particles with a strongly corrugated surface. The
low aqueous solubility of l-leucine leading to a shell on the
surface of the droplet that interferes with the diffusion of
water; therefore, corrugated particles could form. This out-
come was consistent with previous observations.(46,53,69)
Corrugated surface improves the dispersibility of the dry
powder formulations and enhances respirability due to re-
duced interparticulate cohesion (Van der Waals forces),
which is beneficial for particles intended for inhalation.(70)
Antioxidant activity
Owing to its reproducibility and comparability, the
DPPHc assay is an established method for investigating the
antioxidant properties of natural compounds. Due to the H-
donating ability of the antioxidants, a stable reduced DPPH-
H molecule can form. The reaction can be seen visually and
the detection can be carried out using UV-Vis spectropho-
tometer.(71,72) Previous studies confirmed that Api is able to
scavenge the DPPHc free radial even in nanoscale delivery
formulation.(73,74) In general, the scavenging activity is
influenced by concentration and structural features such as
hydrogen donating ability, position, and the degree of
FIG. 8. Next-generation impactor deposition pattern of the spray-dried
BSA-Api formulations.
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hydroxylation.(75,76) To calculate the exact concentration of
remaining DPPHc in the samples, a calibration curve was
plotted with R2 = 0.9999. The time required to reach the
steady state was estimated to be 120 minutes, and the slow
reaction kinetic of Api has been reported.(73) The discolor-
ation of the deep purple DPPHc free radical indicates the
antioxidant properties of free and encapsulated Api.
The inhibition of free radicals by the prepared spray-
dried formulations was compared to the empty BSA-NPs,
methanolic Api solution, and ‘‘empty’’ nanoparticles (Fig. 10).
FIG. 9. Scanning electron microscopy images of raw apigenin (1), excipient-free spray-
dried BSA-Api nanoparticles (2), spray-dried BSA-Api nanoparticles with lactose (3), and
spray-dried BSA-Api nanoparticles with L-leucine (4) 20,000 ·magnification.
FIG. 10. Radical scavenging activity of Apigenin solution, empty BSA na-
noparticles, BSA-Apigenin nanoparticles (NP), and spray-dried nanoparticles
(SD) with excipients. The antioxidant activity is expressed as the inhibition of
DPPHc free radical in percent. DPPHc, 2,2-diphenyl-1-picrylhydrazyl.
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It can be seen that the free and encapsulated Api has similar
scavenging activity, moreover, spray drying did not result in
the loss of scavenging activity. It has been reported that
serum albumin is a physiological circulating antioxidant in
the body,(77) which is confirmed by the inhibition capacity of
the empty BSA-NPs observed. Similar results were reported
when encapsulating rutin and kaempferol(78) or quercetin,(17)
where the antioxidant activity of the flavonoids are retained
by BSA. It can be concluded that the antioxidant activity of
Api is preserved, moreover, slightly enhanced by the BSA.
Conclusion
In this study, novel apigenin containing albumin nano-
particles were prepared for inhalation against lung injury
caused by oxidative stress. Apigenin was recently classified
as a BCS II drug with prominent antioxidant and anti-
inflammatory properties in the lung. The obtained results
confirmed that incorporation of apigenin into the biocom-
patible albumin nanoparticles resulted in high encapsulation
efficiency, and therefore, it could be an attractive tool for
delivery. Moreover, the spray-dried nanoparticles possess
good ability to redisperse in aqueous media and size of the
particles was preserved in the nanometer size range.
The influence of dispersibility enhancers on the physi-
cochemical properties and in vitro pulmonary deposition
was investigated and compared to the excipient-free for-
mulation. The obtained in vitro pulmonary depositions
proved that the developed BSA-NP dry powders are po-
tentially able to carry apigenin deep in the lung, reaching the
respiratory zone. The use of novel excipient amino acid l-
leucine resulted in enhanced aerodynamic properties over
the traditional lactose monohydrate, indicating that the na-
ture of the excipients and morphology of the particles play a
significant role in the formulation of nanoparticles for pul-
monary delivery. In addition, the solubility and dissolution
characteristics of apigenin from nanoparticles were deter-
mined in mSLF dissolution media, the cospray-dried ex-
cipients played an important role.
The dissolution rate was increased by the water soluble
lactose and decreased by l-leucine, which has low water
solubility. Therefore, the use of excipients should be taken
into consideration, and may not be required in case of al-
bumin nanoparticles. We further confirmed that the antiox-
idant activity is retained; thus, the potential of albumin
nanoparticles as an effective pulmonary delivery system for
flavonoids such as apigenin.
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